Major US breast cancer drug trial disappoints
Saturday 11 December 2010
A major trial that aimed to see if a common bone-strengthening drug could help prevent recurrences of breast cancer found it did not benefit most patients, doctors said Thursday.
The five-year study, known as the AZURE trial, followed 3,360 women with advanced breast cancer who had already undergone surgery.
The study randomly assigned some to take the osteoporosis drug Zometa, also known as zoledronic acid, in addition to standard therapy. Zometa is made by the Swiss pharmaceutical giant Novartis.
The hope was that it would prevent cancer from resurfacing, as it often does, in a survivor's bones.
But the American Association for Cancer Research said the drug was found to have no impact on "disease-free survival" for the group as a whole.
"In the larger population, we did not see a difference," said Robert Coleman, professor of medical oncology at the University of Sheffield in England, who presented the results at a conference in San Antonio, Texas.
He added, however, that there was a slight difference across age groups, with older patients faring slightly better on the drug.
The 30 percent of the group who were post-menopausal by at least five years, 1,101 in all, saw a 29 percent improvement in overall survival, which was "unlikely to be a chance finding," Coleman said.
"We will clearly want to investigate further in this population."
He added, however, that "the young patients are getting no benefit. If anything they are doing worse."
Zoledronic acid is a bisphosphonate that works by lowering the amount of calcium released by the bones into the blood.
It is used to treat high blood calcium levels that can coincide with cancer and also to prevent fractures in patients with cancer.
elephant appealThe first 23 lots in our charity auction have now gone. But there are 22 more still up for grabs
From rainforests and reefs to beaches and boat trips
comedy'Fresh Meat' star sees off stiff competition from Alan Carr, David Mitchell, Graham Norton, Lee Mack and Sarah Millican to win top prize
Life & Style blogs
The 50 Best Christmas Gifts for Women
Foodini: the £835 machine that 'prints' food in your kitchen
Physicists discover 'clearest evidence yet' that the Universe is a hologram
In pictures: Christmas in London through the ages
Pirate Bay sets sail for Ascension Island after SX domain name seized by authorities
- 1 French café starts charging extra to rude customers
- 2 Australia incest case: Deformed children found in remote farming community after generations of inbreeding
- 3 Physicists discover 'clearest evidence yet' that the Universe is a hologram
- 4 Woman who miscarried in private prison 'made to clean up after herself,' court told
- 5 Fox News presenter tells viewers it is a 'fact' that both Jesus and Santa Claus are white
- < Previous
- Next >
£50000 - £70000 per annum + benefits+bonus+package: Harrington Starr: C#.NET D...
Negotiable: Capita Education Resourcing Permanent Team: Teacher of Business St...
Negotiable: Capita Education Resourcing Permanent Team: This is a full-time te...
Negotiable: Capita Education Resourcing Permanent Team: Teacher of English - S...